Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM

Opinion
Video

Panelists discuss how the CEPHEUS trial’s demonstration of improved progression-free survival with daratumumab-VRd versus VRd alone in transplant not-preferred NDMM provides compelling evidence for quadruplet therapy in this setting, though considerations of cost, toxicity management, and patient selection remain important factors in implementation.

Video content above is prompted by the following:

  • What are your impressions of the CEPHEUS data that was recently presented?
  • How might this impact your clinical practice?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
2 experts in this video
2 experts in this video
2 experts in this video
Related Content